Tango Therapeutics stock reaction and recent performance

Tango Therapeutics (TNGX) has drawn investor attention after recent trading moves, with the stock closing at US$22.76 on the latest trading day. The price change offers a fresh prompt to reassess the company's recent performance.

Over the past month, Tango Therapeutics stock has fallen about 22%, while the past 3 months show a gain of roughly 13%. Year to date, the stock return is about 155%, and the 1-year total return is about 233%.

The sharp year to date share price return, alongside a much weaker 1 month share price return, suggests that momentum in Tango Therapeutics is cooling in the short term, while the longer term total shareholder return remains far stronger than its recent pullback implies.

Compare the sharp share price swings of Tango Therapeutics with a curated group of other high potential stocks using the 21 high quality undiscovered gems to see what else is moving under the radar.

The sharp year to date rise and recent pullback in Tango Therapeutics raises a simple question. Is this a reset in sentiment around an early-stage biotech, or a price shift that better reflects its fundamentals and current valuation?

Preferred price to book multiple for Tango Therapeutics: is it justified?

Tango Therapeutics is trading on a P/B of 3.7x, which screens as expensive compared with the broader US Biotechs industry average of 2.5x, even after the recent share price pullback.

The P/B ratio compares a company's market value with its net assets on the balance sheet. For a clinical stage biotech such as Tango Therapeutics that is still loss making, investors often lean on P/B because earnings based metrics are less meaningful while products are in development.

The current 3.7x P/B suggests the market is placing a higher value on Tango Therapeutics equity than the sector average, despite the company reporting a loss of $123.7m on revenue of $53.8m. Part of that gap may reflect expectations for the forecast 68.6% annual revenue growth and the precision oncology pipeline, although analysts also expect Tango Therapeutics to remain unprofitable over the next three years, which leaves that premium more exposed to sentiment shifts.

Compared with the US Biotechs industry average P/B of 2.5x, Tango Therapeutics trades on a meaningfully richer multiple. That implies the stock is priced above the sector norm for its current balance sheet, even when set against peer averages where the company is described as better value than some close comparators on this measure.